•
Dec 31, 2020
Agenus Q4 2020 Earnings Report
Transitioned to a commercial company with the initiation of rolling BLA filing for balstilimab monotherapy and reported positive data on multiple programs.
Key Takeaways
Agenus reported a net loss for the fourth quarter of 2020, and the initiation of their rolling BLA filing for balstilimab monotherapy.
Initiated rolling BLA filing for balstilimab monotherapy.
Reported positive data on multiple programs.
BLA completion expected in first half of 2021.
AGEN1777 (Anti-TIGIT bispecific) slated for IND filing in 2Q 2021.
Agenus
Agenus
Forward Guidance
Agenus anticipates completing the balstilimab monotherapy BLA filing in the first half of 2021 and expects commercialization to provide a solid foundation for developing their next-generation pipeline.
Positive Outlook
- Completion of balstilimab monotherapy BLA filing expected in the first half of 2021.
- Commercialization of balstilimab is anticipated.
- Next-generation anti-CTLA-4 AGEN1181 shows superior potential.
- Anti-TIGIT bispecific AGEN1777 has best-in-class potential.
- iNKT cell therapy trials underway for COVID-19 and cancer.